article
Posdinemab, being investigated by Johnson & Johnson, has received FDA…
4 February 2025 | By Drug Target Review
Posdinemab, being investigated by Johnson & Johnson, has received FDA fast-track status. Hear from Dr Fiona Elwood as she explains how Johnson & Johnson’s precision medicine approach could transform Alzheimer’s treatment.